Project-focused activity and knowledge tracker: A unified data analysis, collaboration, and workflow tool for medicinal chemistry project teams

Journal of Chemical Information and Modeling

Volumn 49, Issue 12, 2009, Pages 2639-2649

  Brodney, Marian D ^a   Brosius, Arthur D ^a   Gregory, Tracy ^a   Heck, Steven D ^a   Klug McLeod, Jacquelyn L ^a   Poss, Christopher S ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ANALYSIS; DECISION MAKING; DIGITAL STORAGE; INFORMATION ANALYSIS; MOLECULES;

AUTOMATED DATA; COLLABORATION ENVIRONMENTS; DRUG DISCOVERY; DRUG MOLECULES; END-USER APPLICATIONS; INTEGRATED SERVICE; MEDICINAL CHEMISTRY; TEAM COMMUNICATION;

DATA SHARING;

ARTICLE; CHEMISTRY; COMPUTER INTERFACE; COOPERATION; DRUG DESIGN; GROUP PROCESS; INDUSTRY; INFORMATION RETRIEVAL; INTERPERSONAL COMMUNICATION; KNOWLEDGE; METHODOLOGY; ORGANIZATION AND MANAGEMENT; STATISTICS; SYSTEM ANALYSIS;

CHEMISTRY, PHARMACEUTICAL; COMMUNICATION; COOPERATIVE BEHAVIOR; DRUG DESIGN; GROUP PROCESSES; INDUSTRY; INFORMATION STORAGE AND RETRIEVAL; KNOWLEDGE; STATISTICS AS TOPIC; USER-COMPUTER INTERFACE; WORKFLOW;

EID: 73349100019     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci9002443     Document Type: Article

References (25)

1. Waller, C. L.; Shah, A.; Nolte, M. Strategies to support drug discovery through integration of systems and data. Drug Discovery Today 2007, 12, 634-639. (Pubitemid 47243705)
2. Agrafiotis, D. K.; Alex, S.; Dai, H.; Derkinderen, A.; Farnum, M.; Gates, P.; Izrailev, S.; Jaeger, E. P.; Konstant, P.; Leung, A.; Lobanov, V. S.; Marichal, P.; Martin, D.; Rassokhin, D. N.; Shemanarev, M.; Skalkin, A.; Stong, J.; Tabruyn, T.; Vermeiren, M.; Wan, J.; Xu, X. Y.; Yao, X. Advanced biological and chemical discovery (ABCD): centralizing discovery knowledge in an inherently decentralized world. J. Chem. Inf. Model. 2007. 47, 1999-2014.
3. Sander, T.; Freyss, J.; von Korff, M.; Reich, J. R.; Rufener, C. OSIRIS, an entirely in-house developed drug discovery informatics system. J. Chem. Inf. Model 2009, 49, 232-246.
4. Robb, G. Hypothesis-driven drug design using wiki-based collaborative tools. Presented at the UK-QSAR and ChemoInformatics Group Meeting, May 14, 2009. http://www.documentarea.com/qsar/Grobb-Ukqsar-May09.pdf (accessed June 18, 2009).
5. Barber, C. G.; Gardner, B.; Haque, N. "OnePoint" - Combining OneNote and SharePoint to facilitate knowledge-transfer. Drug Discovery Today 2009, 14, 845-850.
6. All chemical structures appearing in this paper have been previously disclosed in one or more of the following publications:
7. (a) Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Rogier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-lH- pyrazol-l-vl]benzenesulfonamide (SC-58635, CeIecoxib). J. Med. Chem. 1997, 40, 1347-1365.
8. (b) Talley, J. J.; Penning, T. D.; Collins, P. W.; Rogier, D. J., Jr.: Malecha, J. W.; Miyashiro, J. M.; Bertenshaw, S. R.; Khanna, I. K.; Graneto, M. J.; Rogers, R. S.; Carter. J. S. Substituted pyrazolyl benzenesulfonamides. U.S. Patent 5,466,823, Nov 14, 1995.
9. All assay data appearing in the figures was randomly generated. All text appearing in the hypothesis, knowledge, notes, design criteria, measure of success and other such areas in the figures are for illustration purposes only and are not intended to reflect the properties of the molecules shown therein. The authors of this work played no role in the discovery or development of Celebrex or its analogues.
10. The pivot table process described herein has been presented in preliminary form previously: Klug-McLeod, J. Data integration to facilitate project team decision making. Presented at (a) the Accelrys Science Forums 2009, Boston, MA, June 9, 2009,
11. (b) the Massachusetts Biotechnology Council, Cambridge, MA, April 2, 2009, and
12. (c) the 2009 Accelrys User Group Meeting 2009, February 19, 2009.
13. Howe, W. J. An integrated desktop computing environment for medicinal and computational chemists. Presented at the American Chemical Society National Meeting- Philadelphia, PA, August 18, 2008: Abstract CINF 32.
14. Pipeline Pilot, versions 6.1, 7.0, and 7.5; Accelrys, Inc.: San Diego, CA, 2006, 2008, and 2009, respectively.
15. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431. (Pubitemid 38510559)
16. Spotfire DecisionSite, version 9.0: TlBCO Software Inc.: Palo Alto, CA, 2007.
17. ISIS/Draw, version 2.4: Symyx Technologies Inc.: Sunnyvale, CA, 2001.
18. Smith, G. F. Enabling HTS hit follow up via chemo informatics, file enrichment, and outsourcing. Presented at the Royal Society of Chemistry High Throughput Medicinal Chemistry II Symposium, May 9, 2006. htto://www. mmsconferencing.com/pdf/htmc/g.smith.pdf (accessed March 19, 2009).
19. A structure is considered "unique" if it represents a novel stereoisomer, tautomer, or ionization state of a previously registered compound. Mixtures of stereoisomers (typically racemic mixtures of enantiomers) are also considered distinct from the individual stereoisomers themselves. The fact that tautomeric forms are considered distinct is seen as a limitation and will be addressed in a future version of the VCP.
20. Accord Chemistry Cartridge, version 7.0; Accelrys, Inc.: San Diego. CA, 2008.
21. The current implementation attempts to match VCP and ADP molecules by comparison of the Pipeline Pilot CANONICAL SMILES representations of the parent fragments (non-salt forms). Unfortunately, this method may fail to match molecules with multiple chiral centers and/or multiple tautomeric forms, based on differences in how these molecules were drawn during the original registration process. Future development is planned to address these shortcomings.
22. Cerep. http://www.cerep.fr/cerep/users/pages/ProductsServices/ Industrialization.asp (accessed March 19, 2009).
23. FileMaker Pro, version 9.0; FileMaker, Inc.: Santa Clara, CA, 2007.
24. PCAT, Pfizer Compound Analysis Tool, version 3.5: Pfizer Global Research & Development: Cambridge, MA, 2009; PCAT is a tool for clustering, organizing, and visualizing molecules with their associated properties and biological activities.
25. RGate, version 2.7.1.3.0; Pfizer Global Research & Development: Groton, CT, 2009.